Celyad SA Company Profile (NASDAQ:CYAD)

About Celyad SA (NASDAQ:CYAD)

Celyad SA logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYAD
  • CUSIP: N/A
  • Web: www.celyad.com
Capitalization:
  • Market Cap: $435.61 million
  • Outstanding Shares: 9,520,000
Average Prices:
  • 50 Day Moving Avg: $42.65
  • 200 Day Moving Avg: $27.77
  • 52 Week Range: $16.31 - $48.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9.54 million
  • Price / Sales: 44.91
  • Book Value: $10.93 per share
  • Price / Book: 4.12
Profitability:
  • EBIDTA: ($27,060,000.00)
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 7.57%
  • Quick Ratio: 7.57%
Misc:
  • Average Volume: 2,236 shs.
  • Beta: 1.69
  • Short Ratio: 1.95
 

Frequently Asked Questions for Celyad SA (NASDAQ:CYAD)

What is Celyad SA's stock symbol?

Celyad SA trades on the NASDAQ under the ticker symbol "CYAD."

Are investors shorting Celyad SA?

Celyad SA saw a increase in short interest in May. As of May 15th, there was short interest totalling 4,307 shares, an increase of 152.0% from the April 28th total of 1,709 shares. Based on an average daily volume of 3,834 shares, the short-interest ratio is currently 1.1 days.

Who are some of Celyad SA's key competitors?

Who are Celyad SA's key executives?

Celyad SA's management team includes the folowing people:

  • Michel E J Lussier, Chairman of the Board, Co-Founder
  • Christian Homsy MD, Member of the Executive Management Committee, Chief Executive Officer, Executive Director
  • Patrick Jeanmart, Member of the Executive Management Committee, Chief Financial Officer
  • Gaetane Metz, Chief Operating Officer
  • Richard Mountfield, Vice President of Global Regulatory Affairs
  • Peter De Waele, Member of the Executive Management Committee, Vice President - Research & Development
  • Georges Rawadi, Vice President - Business Development
  • Seron Aymeric, Program Manager
  • Philippe Dechamps, Chief Legal Officer
  • Roland Gordon-Beresford Ph.D., Regulatory Affairs and IP Director

When did Celyad SA IPO?

(CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Who owns Celyad SA stock?

Celyad SA's stock is owned by a number of of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (3.93%). View Institutional Ownership Trends for Celyad SA.

Who bought Celyad SA stock? Who is buying Celyad SA stock?

Celyad SA's stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Celyad SA.

How do I buy Celyad SA stock?

Shares of Celyad SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celyad SA's stock price today?

One share of Celyad SA stock can currently be purchased for approximately $45.00.


MarketBeat Community Rating for Celyad SA (NASDAQ CYAD)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Celyad SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celyad SA (NASDAQ:CYAD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
12/1/2015Maxim GroupReiterated RatingBuyN/AView Rating Details
(Data available from 6/24/2015 forward)

Earnings

Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Celyad SA (NASDAQ:CYAD)
Current Year EPS Consensus Estimate: $-5.16 EPS
Next Year EPS Consensus Estimate: $-4.03 EPS

Dividends

Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Celyad SA (NASDAQ:CYAD)
Latest Headlines for Celyad SA (NASDAQ:CYAD)
Source:
DateHeadline
finance.yahoo.com logoCelyad publishes additional pre-clinical data in support of THINK trial
finance.yahoo.com - June 21 at 5:57 PM
streetinsider.com logoCelyad SA (CYAD) Announces Early Results at First Dose Level of Solid Arm of THINK Trial
www.streetinsider.com - June 19 at 1:56 PM
finance.yahoo.com logoCelyad reports promising early results at first dose level of the solid arm of the THINK trial
finance.yahoo.com - June 19 at 1:56 PM
finance.yahoo.com logo3 Biotech Stocks That More than Doubled Year to Date
finance.yahoo.com - June 19 at 1:56 PM
americanbankingnews.com logo Celyad SA (CYAD) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 16 at 10:22 AM
americanbankingnews.com logoCelyad SA (CYAD) Short Interest Up 152.0% in May
www.americanbankingnews.com - June 3 at 5:28 PM
americanbankingnews.com logoZacks: Celyad SA (CYAD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 31 at 8:34 AM
streetinsider.com logoCelyad SA (CYAD) Receives Additional US Patent for Cancer Treatment based on TCR-deficient CAR-T Cells
www.streetinsider.com - May 30 at 11:47 AM
finance.yahoo.com logoCelyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
finance.yahoo.com - May 30 at 11:47 AM
finance.yahoo.com logoCelyad Announces First Quarter 2017 Business Update
finance.yahoo.com - May 19 at 8:21 AM
americanbankingnews.com logoZacks: Analysts Set $35.67 Target Price for Celyad SA (CYAD)
www.americanbankingnews.com - May 16 at 4:30 PM
streetinsider.com logoCelyad SA (CYAD) Granted FDA Fast Track Status for C-Cure
www.streetinsider.com - May 11 at 10:15 PM
businesswire.com logoCelyad SA: Notice of Extraordinary General Meeting to be held on the 12 June 2017
www.businesswire.com - May 11 at 2:47 AM
finance.yahoo.com logoFDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®
finance.yahoo.com - May 11 at 2:47 AM
americanbankingnews.com logoCelyad SA (CYAD) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 6:10 PM
finance.yahoo.com logoCelyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
finance.yahoo.com - May 2 at 7:51 PM
americanbankingnews.com logoZacks: Celyad SA (CYAD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 1 at 6:10 PM
americanbankingnews.com logoCelyad SA (CYAD) Receiving Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 30 at 7:50 AM
finance.yahoo.com logoCelyad initiates second dose escalation in THINK trial in first US patient
finance.yahoo.com - April 28 at 3:13 AM
americanbankingnews.com logoCelyad SA (CYAD) Earning Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 24 at 11:19 AM
americanbankingnews.com logoCelyad SA (CYAD) Given Media Sentiment Score of 0.56
www.americanbankingnews.com - April 18 at 9:35 AM
americanbankingnews.com logoCelyad SA (CYAD) Receives Media Sentiment Score of -0.22
www.americanbankingnews.com - April 15 at 11:21 AM
finance.yahoo.com logoCelyad SA :CYAD-US: Earnings Analysis: For the six months ended December 31, 2016 : April 10, 2017
finance.yahoo.com - April 10 at 12:05 PM
americanbankingnews.com logo Brokerages Anticipate Celyad SA (CYAD) Will Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 8 at 8:44 AM
finance.yahoo.com logoCelyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017
finance.yahoo.com - March 23 at 2:45 AM
americanbankingnews.com logo Analysts Set $35.67 Target Price for Celyad SA (CYAD)
www.americanbankingnews.com - March 22 at 10:26 AM
finance.yahoo.com logoUSPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
finance.yahoo.com - March 16 at 3:07 AM
streetinsider.com logoCelyad SA (CYAD) Says DFA Authorized Initiation Of THINK Trial in ... - StreetInsider.com
www.streetinsider.com - March 8 at 5:23 PM
finance.yahoo.com logoCelyad Obtains FDA Approval to Initiate NKR-2 CAR T cells THINK Trial in US
finance.yahoo.com - March 8 at 5:23 PM
finance.yahoo.com logoCelyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
finance.yahoo.com - March 8 at 2:38 AM
us.rd.yahoo.com logoCelyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
us.rd.yahoo.com - February 16 at 1:47 PM
streetinsider.com logoCelyad SA (CYAD) Reports Activation of Second Site in Belgium for ... - StreetInsider.com
www.streetinsider.com - January 13 at 3:04 AM
streetinsider.com logoCelyad SA (CYAD) Reports Activation of Second Site in Belgium for THINK Trial
www.streetinsider.com - January 12 at 10:02 PM
finance.yahoo.com logoCelyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium
finance.yahoo.com - January 11 at 5:04 PM
publicnow.com logoCelyad Announces Registration of the first patient in the Belgian THINK trial
us.rd.yahoo.com - January 5 at 3:42 AM
finance.yahoo.com logoEdison Issues ADR Update on Celyad (CYAD)
finance.yahoo.com - December 13 at 9:26 AM
us.rd.yahoo.com logoCELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
us.rd.yahoo.com - December 7 at 9:37 AM
us.rd.yahoo.com logo3:54 am Celyad SA presents new data from its CAR-T NKR-2 Phase I Trial; demonstrates strong safety signals, including no cases of cytokine release syndrome
us.rd.yahoo.com - December 7 at 9:37 AM
globenewswire.com logoCELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting - GlobeNewswire (press release)
globenewswire.com - December 6 at 11:40 AM
streetinsider.com logoCelyad SA (CYAD) Receives Approval in Belgium to Commence NKR-2 CAR-T Clinical Trial - StreetInsider.com
www.streetinsider.com - November 21 at 9:29 AM
streetinsider.com logoCelyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016
www.streetinsider.com - November 7 at 11:14 PM
streetinsider.com logoCelyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016 - StreetInsider.com
www.streetinsider.com - November 7 at 4:18 PM
finance.yahoo.com logoCelyad's NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016
finance.yahoo.com - November 7 at 6:50 AM
finance.yahoo.com logo3:08 am Celyad SA to present encouraging data in NKR-2 Phase I Safety Trial at ASH
finance.yahoo.com - November 7 at 6:50 AM

Social

Chart

Celyad SA (CYAD) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by MarketBeat.com Staff